Autologous osteoblastic cell therapy - Bone Therapeutics

Drug Profile

Autologous osteoblastic cell therapy - Bone Therapeutics

Alternative Names: PREOB; PREOB cells

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Bone Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Femur head necrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Femur head necrosis
  • Phase II/III Non-union fracture
  • Phase II Osteoporosis

Most Recent Events

  • 16 Sep 2016 Efficacy data from a clinical trial in Femur head necrosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research-2016 (ASBMR-2016)
  • 12 Aug 2013 Phase-II/III clinical trials in Non-union fracture in Netherlands (Intraosseous)
  • 01 Jun 2012 Phase-II/III clinical trials in Non-union fracture in Belgium (Intraosseous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top